Fig. 2: Viral kinetics and plasma antibody levels following fully and partially neutralizing antibody infusion.

a,b, Peak plasma VL (a) and rate of viremia increase (upslope; b) measured from synchronized VL curves when VL was equal to 1,000 copies per millilitre. Animals in the antibody treatment group were pooled according to whether they received the fully neutralizing ITS103.01 (groups 3 and 5) or the partially neutralizing mAbs (groups 2 and 4). Group 1 (control) animals are shown separately. For each graph, groups were compared by two-tailed one-way analysis of variance, and all pairwise comparisons were assessed using Tukey’s honest significant difference (HSD) test; significant (adjusted P < 0.05) differences are indicated. c,d, Antibody half-life in days of infused mAbs (c) and median longitudinal plasma mAb levels (d) (error bars indicate range; n = 6 animals for ITS01, n = 18 for ITS06.02, n = 12 for ITS103.01) with respect to the day of first viral challenge. For animal G4-3, no ITS01 half-life is shown, and the longitudinal plasma mAb levels for this animal were excluded from the median as high endogenous reactivity to the ITS01 anti-idiotypic antibody prevented calculation of the mAb decay curve (Extended Data Fig. 1). e, Plasma ITS103.01 levels measured at the time of the likely challenge causing a viral blip, at the time of the viral blip, at the challenge that probably led to infection and at the time of acute viremia (VL equal to 1,000 copies per millilitre). In each graph, the fold increase of the median mAb concentration relative to the ITS103.01 IC₈₀ (marked by a dotted line for reference) is indicated above the data points (Extended Data Figs. 1 and 2 and Supplementary Table 1). In a–c and e, data points for individual animals are shown and coloured according to treatment group (n = 6 animals per group in total). The overlaid boxes and middle line indicate the interquartile range (IQR) and median, respectively, and the whiskers indicate the range.

Source Data